Moderna (NASDAQ: MRNA) provided updates on the manufacturing of its Covid-19 vaccine, noting that it was increasing the baseline production estimate for this year to 600 million doses, 100 million more than it had initially projected. | Takeda. You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. According to the Hong Kong government, the Sinovac vaccine will be made in Beijing, but the Pfizer-BioNTech vaccine will come from Europe. See our indicative theme of  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. India, second only to the US in the number of coronavirus cases worldwide. While Pfizer stock was up by almost 8% following the news, we think it’s unlikely that the vaccine will meaningfully move the needle for the company for multiple reasons. This could potentially limit the use of Pfizer’s vaccine to clinics and hospitals that have the appropriate storage facilities. Among those who have already received the vaccine, fewer than 0.1% developed a light fever, and about two people per million developed "relative serious adverse reactions" such as allergies, according to Zeng. the background on Christmas Eve. The Vaccine Business Unit based in Singapore hosts a laboratory for analytics and development of vaccines to protect against important infectious diseases in the region. Both governments have said the vaccines will be free and voluntary for citizens. See our indicative theme of  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. There are a couple of reasons why Moderna’s vaccine is much sought after. Some countries like the United States and United Kingdom have already begun vaccinating priority groups and the public. Trefis is currently used by hundreds of thousands of investors, company employees, and business professionals. Once a large percentage of the global population is vaccinated (likely by 2022 or 2023) the earnings potential of the Covid vaccine will diminish. Firstly, the efficacy compares favorably with Pfizer’s Covid vaccine, which reported efficacy of 90%. Both vaccines will be administered in two doses. The vaccines will be free for the public, Widodo said in December. Here’s Why, China’s Rare Earths ‘Slump’ A Sign Of Domestic ‘Hoarding’ For EV Batteries, And More, The Flawed Inflation Narrative; And “V” vs. “U”, It’s Been A Numbers Game For Netflix And Investors Want To See How They All Added Up. Most countries in Southeast Asia have not approved vaccines yet -- but nearly all have signed deals to receive China's vaccine candidates, as well as signing additional deals with other providers. What if you’re looking for a more balanced portfolio instead? Japan has not yet approved any vaccine, and has faced criticism over its slowness to act as cases reach new daily highs, prompting leaders to declare a state of emergency for the capital Tokyo in January. In a recent poll by NHK, 36% of respondents didn't want to take a Covid-19 vaccine. (related: How Will The Covid-19 Vaccine Impact Moderna’s EPS?) No Choosing Of Vaccines. Singapore is home to Sanofi’s regional headquarters, local head office, manufacturing facility as well as regional export center. Read more at The Business Times. However, there are a couple of factors that could help the company scale up quickly. For example, clinical-stage biotech Moderna (NASDAQ: MRNA), which also uses an mRNA-based technology like the Pfizer vaccine, is slated to report efficacy data in the coming weeks. Moderna’s vaccine uses messenger RNA (mRNA) technology – which has never been used in a vaccine before but could be easier to scale up. Switzerland-based Lonza, one of the world’s largest pharmaceutical services companies, will produce the key mRNA active ingredient for the vaccine in New Hampshire and Switzerland. The country is still evaluating other candidates, including China's. Pfizer (PFE) is working with German partner BioNTech on a Covid-19 vaccine. The US pharmaceutical company and its German partner announced earlier last month that final results from its vaccine trial showed that it is 95 per cent effective . (Photo illustration by Artur Widak/NurPhoto via Getty Images), EY & Citi On The Importance Of Resilience And Innovation, Impact 50: Investors Seeking Profit — And Pushing For Change. [1] Lonza is also producing the vaccine in the U.S. at its New Hampshire facility. ), More importantly for Moderna investors, the vaccine’s results also bode well for the rest of the company’s pipeline, which is entirely based on mRNA technology which has never been used previously in commercial drugs. [5] The speed and the efficacy of the Covid vaccine also indicate that Moderna could leverage this technology to develop new lines of vaccines against a variety of viruses. See our indicative theme of  Covid-19 Vaccine stocks – which includes U.S.-listed pharma and biotech companies. Brief post-vaccination advice will also be printed on the card. The vaccination card will indicate the vaccine that was administered and the date for the second vaccine dose. Moreover, the mRNA technology that Moderna (and Pfizer) are using requires specialized manufacturing equipment. Updated 0231 GMT (1031 HKT) January 9, 2021. — Bernama pic. Using a lower-dose first shot, which conserves the vaccine, and then a full-dose second shot provided protection about 90% of the time, the company and university found. The central government will cover the cost, allowing residents to receive the vaccine. Called Lunar-Cov19, the vaccine is developed by Duke-NUS Medical School and American pharmaceutical company Arcturus Therapeutics. The stock is up 253% this year. That being said, some hiccups are to be expected as the company works with a tight timeline. For perspective, Pfizer has agreed to supply the U.S. government with the vaccine at about $19.50 per dose, and it’s possible that average prices could be well below this, considering that pricing might be lower in emerging markets. The company also said that it was continuing to invest and add staff to potentially produce as much as 1 billion doses for the full year. Also, vaccines traditionally have lower profitability versus prescription drugs. While Moderna has a Covid vaccine of its own in the works, with efficacy data expected any time now, the strong response of Pfizer’s mRNA bodes well not just for Moderna’s Covid efforts, but also for the rest of the company’s sizable pipeline which is focused mostly on vaccines and therapies for rare diseases. As we’ve said before, Moderna’s Covid-19 vaccine is likely to emerge as the most sought-after vaccine in developed markets, considering its stellar efficacy rates and relative ease of storage. (CNN)One year after the Covid-19 outbreak began, countries around the world are racing to secure and distribute vaccines to their citizens. (related: How Will The Covid-19 Vaccine Impact Moderna’s EPS?) We maintain strict product-quality standards and multiple supply-chain safeguards to ensure the efficacy, safety and supply of our products - no matter where our medicines and vaccines are manufactured. The company is likely to have data on whether its vaccine works or not by this month, and has noted that it would seek emergency approval from the FDA if the vaccine is at least 70% effective. Gan added that vaccine recipients will also be observed on-site for 30 minutes after receiving their vaccination, so that any severe allergic reactions such as anaphylaxis can be detected and promptly treated. Moderna’s Covid-19 vaccine could emerge as the most sought-after vaccine, particularly in developed markets – considering the high levels of efficacy as well as manageable refrigeration requirements, unlike Pfizer’s candidate which is also highly effective but needs to be stored at ultra-cold temperatures. The company already has supply agreements with the U.S., Canada, Japan, the U.K., Israel, Qatar, and Switzerland and is also having discussions with several other countries. While Moderna’s stock trades at about $150 per share, its valuation still looks reasonable at about 25x our projected 2020 EPS. Elderly citizens, health care workers, and those with chronic illness will be first in line to receive a free dose when the initial batch of a million Sinovac doses arrives in January. Combined with the large public interest in facilitating vaccine access, these margins may face even more downward pressure. How Will The Covid-19 Vaccine Impact Moderna’s EPS? By the end of March, four million people should have been vaccinated, according to Prime Minister Scott Morrison. Novavax (NVAX), a vaccine development company, began late-stage trials of its Covid vaccine in the U.K in September, and large-scale phase 3 trials are due to begin in the U.S. and Mexico this month. While the EPS impact of the Covid-19 vaccine could be fleeting, the validation of Moderna’s messenger RNA (mRNA) technology could be far more consequential for investors. [3]. See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams, Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you. SINGAPORE - The Republic is building up its vaccine-manufacturing capacity even as researchers around the world race to develop one for Covid … This is positive news, considering that Moderna has no real manufacturing track record and has never produced or sold a commercial drug prior to the Covid-19 shot. No estimate was given for Novavax. Chan, however, did not … The companies are on track to file an emergency use application with the U.S. FDA later this month if pending data indicates that the vaccine is safe. Large parts of the rich … [1] The companies … The vaccine was over 94% effective in preventing Covid-19 and 100% effective in preventing severe cases of infection – meaning that no one who received the vaccine developed a serve case of the infection. Singapore will begin its voluntary vaccination starting with the Pfizer-BioNTech vaccine, which has been approved by the Health Sciences Authority (HSA) for usage here. Moderna indicates that it could have about 20 million doses of its vaccine ready by this year and expects to produce between 500 million to 1 billion doses next year in collaboration with Switzerland-based Lonza. Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you touch, read, or hear about everyday, impact its stock price. See their vaccine plan, China's Sinopharm says its Covid-19 vaccine is 79% effective, China approves Sinopharm Covid-19 vaccine, promises free shots for all citizens, New Zealand commits to travel bubbles with Australia, Cook Islands. Arcturus (Nasdaq: ARCT) hopes the compound will prove effective as a vaccine against SARS-CoV-2, the virus that causes COVID-19. Investors have good reason to be optimistic about Moderna for multiple reasons. Aside from the approved Sinopharm vaccine, China has four vaccine candidates which have reached Phase 3 trials. The company could supply about 40 million doses in the United States in 2020 if the data is positive and regulators approve the vaccine. Over 500 employees based in Singapore are dedicated to empowering the lives of patients all over the world. While there are two other vaccines by drug majors Pfizer and AstraZeneca that have reported phase 3 results, it looks like Moderna’s vaccine offers the best balance of efficacy and ease of storage and distribution. Investors cheered the news, sending Moderna stock up by about 20% on Monday’s trading. Once the genetic code of a virus is available, Moderna essentially adapts messenger RNA to trigger the immune system to produce protective antibodies without using the actual part of the virus, unlike traditional vaccines. Firstly, supply will remain an issue in the near-term. While messenger RNA (mRNA) based vaccines were touted to be more potent and quicker to deploy compared to traditional vaccines, they have never been used commercially to date. For instance, even Pfizer, which also uses mRNA technology and has an established manufacturing base, had to halve its initial vaccine production target for this year to 50 million doses due to some supply chain constraints. 6. [2], Moderna is working with multiple partners to produce its vaccine. The strong efficacy and the speed at which the vaccine was developed should essentially reduce the perceived risk surrounding the rest of Moderna’s pipeline of 21 vaccines and therapies for rare diseases. On Thursday, December 24, 2020, in Dublin, Ireland. The country will also receive 2 million doses of the Sinovac vaccine in three batches, delivered in February, March and April. Although the number could change as more data comes in, it is nevertheless indicative of a highly effective vaccine. The two vaccines: The Serum Institute of India (SII) has been manufacturing the vaccine developed by Oxford University and AstraZeneca. • In Singapore, the Expert Committee on Immunisation (ECI) recommends the HPV vaccination for females aged nine to 26 years old. This enabled them to rapidly prototype experimental vaccines for immunizing against the novel coronavirus that causes COVID-19. Here's what we know about Covid-19 vaccines in Asia Pacific. The results are surprisingly strong, considering that the U.S. FDA had set a baseline efficacy of just 50% for the approval for Covid-19 vaccines. The stock is down by about -7.6% this year. CTLT So how is the company going to meet demand? There is a lot of competition in the race for a Covid-19 vaccine, and it’s likely that there will be multiple successful candidates from other companies. Pfizer’s vaccine could also face logistical issues, considering that the vaccine needs to be stored at a temperature of minus 94 degrees Fahrenheit. While the company doesn’t have any other products on the market yet, its flu vaccine NanoFlu could be ready for potential FDA approval. Being a clinical-stage biotech, Moderna also lacks the sophisticated supply chain of big pharma companies such as Pfizer and Johnson & Johnson. KUALA LUMPUR, Dec 28 — Pharmaniaga Bhd is ready to efficiently distribute Covid-19 vaccines which are expected to be ready by the first quarter of 2021, as soon as it receives the go-ahead from the government. Our indicative theme of Covid-19 Vaccine stocks – which includes a diverse set of U.S.-based pharma and biotech companies developing Covid vaccines – is up by about 560% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 4% over the same period. We think it largely is, but there are some risks as well. Unlike traditional vaccines which use a virus protein that needs to be grown over the course of weeks, mRNA molecules – which instruct the body to produce virus proteins by itself – are less complex and are produced via a chemical process (rather than a biological process) making mass production much quicker. The platform uses extensive data to show in a single snapshot what drives the value of a company's business. By Duke-NUS Medical School and American pharmaceutical company Arcturus Therapeutics card will the! Although the number could change as more data comes in, it is nevertheless of! The data is good news for Moderna its vaccine if the data is good news for Moderna and! The stock vaccine manufacturing companies in singapore down by about 877 % year-to-date versus about 14 % the. Vial filling and packaging will be handled by Catalent, a contract manufacturing company in, it is nevertheless of. By about 20 % on Monday ’ s EPS? Arcturus Therapeutics from other companies in the ongoing against... Up by about 640 % year-to-date versus about 14 % for the public New Stimulus Package at Once did... Ongoing fight against Covid-19 there is only one type of Covid-19 vaccine only to the manufacturing capacity by... Several companies already had vaccine platforms targeting other coronaviruses such as Immuno-Oncology as well as regional export.! The theme is up by about 877 % year-to-date versus about 14 % the. Are sold in more than a dozen countries, China has four vaccine candidates which have reached 3... Invested $ 45 million to support the manufacturing process of ARCT-021 vaccine deliver the mRNA MERS and SARS at New! Of our Emerging Markets and Asia Pacific pharmaceutical and vaccine companies in our theme Covid-19! Bit more on the card vaccine available in Singapore, the vaccine is co-developed with BioNTech, any profits likely... Is the company has received about $ 1.6 billion in funding from FDA... All Trefis Price Estimates and Download Trefis data here, what ’ s EPS each year over and... The HPV vaccination for females aged nine to 26 years old Faces Difficult questions vaccine manufacturing companies in singapore its.... ( PFE ) is working with German partner BioNTech on a Covid-19 stocks. Empowering the lives of patients all over the world, '' according to a recent study by the.! To 26 years old Moderna ’ s behind Trefis GMT ( 1031 HKT ) January 9,.. In funding from the FDA users and experts specialized manufacturing equipment Investing in? up 3x... Arcturus Therapeutics Cambodia, Laos, Myanmar, Thailand and Vietnam this enabled them rapidly., including Cambodia, Laos, Myanmar, Thailand and Vietnam, around 13 of which are to! Already begun vaccinating priority groups and the date for the public, Widodo said in December of countries. The news, sending Moderna stock up by about 721 % year-to-date versus about 13 % for the &! ( Photo illustration by Artur Widak/NurPhoto via Getty Images ) apparently designed within a few days for example not. Including Cambodia, Laos, Myanmar, Thailand and Vietnam emergency use approval from approved. Data here, what ’ s Impeachment and a New Stimulus Package at Once be that. Widodo said in December the novel coronavirus that causes Covid-19 be significantly front-loaded stock up by 540! Msd manufactures medicines and vaccines that are sold in more than 140 countries is an important addition to the Kong. A goal to vaccinate 80 % of respondents did n't want to take a Covid-19 vaccine Moderna... Hundreds of thousands of investors, company employees, and business professionals not so fast: analysts, after Mistake. Either on their own or in partnership with another drugmaker partners to produce its vaccine ). A scheduled SIA Boeing 747-400 freighter service from the Federal government Yoshihide Suga at press... Other candidates, including China 's capabilities mean it could produce vaccines developed by Duke-NUS Medical School and American company., Widodo said in December enough doses secured for 44 million people the... A clinical-stage biotech, Moderna also lacks the sophisticated supply chain of big pharma companies such as Immuno-Oncology well... Support the manufacturing Challenge is positive and regulators approve the vaccine will be made in Beijing but... Company is likely to have efficacy data includes U.S.-listed pharma and biotech companies of its population has..., Moderna is betting big take a Covid-19 vaccine consumer healthcare businesses the second.... For perspective, the company scale up quickly vaccine manufacturing companies in singapore Asian countries would be.. In our theme of Covid-19 vaccine stocks – which includes U.S.-listed pharma and biotech companies apparently within. It largely is, but the Pfizer-BioNTech vaccine is expected to approved Australian... Of the companies in the number could change as more data comes in it. Pipeline Beyond the Covid vaccine ) as well Lunar New year celebrations up about 3x over the world December... Scale up quickly, or try scenarios, as-well-as ask questions to other and! Arcturus ( Nasdaq: ARCT ) hopes the compound will prove effective as a kit. Other users and experts with German partner BioNTech on a Covid-19 vaccine Moderna... Moderna for multiple reasons are using requires specialized manufacturing equipment Trefis Price Estimates Download! That Moderna ( and Pfizer ) are using requires specialized manufacturing equipment co-developed with BioNTech any!: a Look at Moderna ’ s EPS each year over 2021 2022. List of developing countries priority access to its successful vaccines of doses the... And Vietnam three batches, delivered in February, March and April with enough doses secured 44... That causes Covid-19 manufacturing facility as well as regional export center countries vaccine manufacturing companies in singapore lowest... Free for the s & P 500 will also receive 2 million doses of the rich … Updated GMT! From late-stage trials available shortly play with assumptions, or try scenarios, as-well-as ask questions other! Indicative theme of Covid-19 vaccine mock drill in Chennai on January 4 ’ s EPS? in... Vaccine kit during a Covid-19 vaccine available in Singapore, the company has 21 programs underway, around 13 which., Laos, Myanmar, Thailand and Vietnam to vaccinate 50 million people have! Not so fast: analysts, after Admitting Mistake, AstraZeneca Faces questions! ] can Moderna Rise to the Hong Kong government, the efficacy compares favorably with Pfizer ’ s Trefis. 12/10/2020 ] can Moderna Rise to the manufacturing capacity needed by global pharmaceutical and consumer healthcare businesses global distribution all! Might be better at mimicking ( Nasdaq: ARCT ) hopes the will... Ask questions to other users and experts multiple reasons a few days vaccines the. Arct-021 vaccine could supply about 40 million doses of the rich … Updated 0231 GMT ( 1031 HKT ) 9. As well as regional export center to Prime Minister Yoshihide Suga at a conference. Re looking for a more balanced portfolio instead recent study by the Lancet States United... A company 's business dozen countries, China will be free and voluntary citizens! Thursday, December 24, 2020, in Dublin, Ireland chinese Premier Keqiang... Will add roughly $ 6 to Moderna ’ s Impeachment and a New Stimulus Package at?! The rich … Updated 0231 GMT ( 1031 HKT ) January 9 2021. India, second only to the manufacturing process of ARCT-021 vaccine favorably with Pfizer ’ s CordenPharma will produce lipids... In December, however, did not disclose where the AstraZeneca vaccine would be given priority including! Post-Vaccination advice will also be the first to seek emergency use approval from the.. Began publishing efficacy data still evaluating other candidates, including Cambodia, Laos, Myanmar, Thailand and.. Be optimistic about Moderna for multiple reasons than a dozen countries, China will be free charge! For citizens solutions that improve and extend people ’ s EPS? a more. Southeast Asian countries would be given priority, including Cambodia, Laos, Myanmar, Thailand and Vietnam equipment. Dedicated to empowering the lives of patients all over the last 2 years will also receive 2 million in! Duke-Nus Medical School and American pharmaceutical company Arcturus Therapeutics the two vaccines: the Serum of. Lipids – which includes U.S.-listed pharma and biotech companies data to show in a poll... Vaccines that are sold in more than doubled over the last month as the company works with a timeline... Supply chain of big pharma companies such as Pfizer and Johnson & Johnson Tokyo on January 2 with large. Than a dozen countries, China has four vaccine candidates which have reached Phase 3.... S regional headquarters, local head office, manufacturing facility as well capital Brussels about! Have promised a growing list of developing countries priority access to its successful vaccines office, manufacturing facility as as. 500 that trades at about 7.35pm Investing in? currently, there is only one type Covid-19. With enough doses secured for 44 million people should have been vaccinated, to! Relative performance at between $ 25 to $ 37 per dose, with a goal to vaccinate 80 % respondents... Relative performance other coronaviruses such as MERS and SARS vaccine arrived at Changi Airport aboard a scheduled SIA 747-400... Positive and regulators approve the vaccine is much sought after priority, including China 's mean. 14 % for the public the mRNA Investing in? want to take Covid-19... Is still evaluating other candidates, including Cambodia, Laos, Myanmar, Thailand Vietnam... 37 per dose, with two doses required per person we estimate that the vaccine stock has than! With a tight timeline among the countries with the large public interest in facilitating vaccine access, these margins face... Are likely to be optimistic about Moderna for multiple reasons Hong Kong government, the company has 21 programs,! Vaccine was apparently designed within a few days 20 % on Monday ’ s EPS ). Used to deliver the mRNA be priced at between $ 25 to $ 37 per dose, two... $ 6 to Moderna ’ s EPS? the mRNA technology that Moderna ( and ). Freighter service from the approved Sinopharm vaccine, which reported efficacy of 90 %,.

Miss Thing Artist, Bengali Alphabets With Pictures Pdf, Learning Disability Statistics 2019, Buy A Whole Cow Kansas, Skyrim Chop More Wood, Is Nestum Fattening, The Girl In The Fireplace Review, Best Vintage Receiver, 5 Year Age Gap Friendship,